Drugs.com - Clinical Trials

Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy

BRISBANE, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that the primary endpoint was met in the ORIGIN Phase 3 trial of atacicept for the treatment of immunoglobulin A nephropathy (IgAN) in...

Jun 3, 2025 - 22:55
 0
Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy
BRISBANE, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that the primary endpoint was met in the ORIGIN Phase 3 trial of atacicept for the treatment of immunoglobulin A nephropathy (IgAN) in...
Read More

Tags:

Previous Article

ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of...

Next Article

Space Force awards BAE $1.2B for missile warning sats in MEO

Related Posts

Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

Verve Therapeutics Receives U.S. FDA Fast Track Designa...

May 12, 2025  0

BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Cutaneous T-Cell Lymphoma

BioInvent Receives FDA Fast Track Designation for BI-18...

May 18, 2025  0

PIVOT-PO Phase III Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee

PIVOT-PO Phase III Study for Tebipenem HBr Stopped Earl...

Jun 3, 2025  0